Remdesivir administration for Japanese COVID-19 patients undergoing maintenance hemodialysis: a retrospective observation with six case reports

BACKGROUND: The mortality rate of novel coronaviral disease (COVID-19) patients undergoing dialysis is considerably higher than that of patients with normal kidney function. As of August 2021, only remdesivir has been approved in Japan as an antiviral drug for the treatment of COVID-19. However, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Jun, Kimura, Moritsugu, Toya, Tomoyuki, Isozumi, Konomi, Kawaji, Atsuro, Isozaki, Yudai, Fukagawa, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996215/
https://www.ncbi.nlm.nih.gov/pubmed/35433033
http://dx.doi.org/10.1186/s41100-022-00404-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996215/
https://www.ncbi.nlm.nih.gov/pubmed/35433033
http://dx.doi.org/10.1186/s41100-022-00404-9

Ejemplares similares